Title:
AMINO ACID MIXTURE HAVING COAMORPHOUS STRUCTURE
Document Type and Number:
WIPO Patent Application WO/2020/262455
Kind Code:
A1
Abstract:
The present invention provides a means for increasing the solubility of even a poorly soluble amino acid without changing to an expensive peptide and also without changing the pH, and is characterized in that at least two kinds of amino acids have a coamorphous structure.
Inventors:
SEN JUN (JP)
Application Number:
PCT/JP2020/024796
Publication Date:
December 30, 2020
Filing Date:
June 24, 2020
Export Citation:
Assignee:
AJINOMOTO KK (JP)
International Classes:
A61P3/02; A23L2/52; A61K8/44; A61K31/198; A61Q13/00; A61Q19/00; C07C227/44; C07C229/36; C07C277/08; C07C279/14; C07C319/26; C07C323/58; C07D207/16
Domestic Patent References:
| WO2010050168A1 | 2010-05-06 |
Foreign References:
| JP2011500709A | 2011-01-06 | |||
| JPH0764741B2 | 1995-07-12 | |||
| JP3368897B1 | 2003-01-20 |
Other References:
JENSEN, KATRINE TARP ET AL.: "Improving Co-amorphous drug formulations by the addition of the highly water soluble amino acid, proline", PHARMACEUTICS, vol. 6, no. 3, 14 July 2014 (2014-07-14), pages 416 - 435, XP055781257
WU, WENQI ET AL.: "Dipeptides as co-formers in co-amorphous systems", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 134, 31 January 2019 (2019-01-31), pages 68 - 76, XP085555707, DOI: 10.1016/j.ejpb.2018.11.016
LOBMANN, KORBINIAN ET AL.: "Amino acids as co-amorphous stabilizers for poorly water soluble drugs - Part 1: Preparation, stability and dissolution enhancement", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 85, no. 3, 26 March 2013 (2013-03-26), pages 873 - 881, XP028790978, DOI: 10.1016/j.ejpb.2013.03.014
ZHU, SAIJIE ET AL.: "Co-Amorphous Formation of High-Dose Zwitterionic Compounds with Amino Acids To Improve Solubility and Enable Parenteral Delivery", MOLECULAR PHARMACEUTICS, vol. 15, no. 1, 22 November 2017 (2017-11-22), pages 97 - 107, XP055781262
WU, WENQI ET AL.: "On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 535, no. 1-2, 2 November 2017 (2017-11-02), pages 86 - 94, XP085328533
See also references of EP 3991791A4
WU, WENQI ET AL.: "Dipeptides as co-formers in co-amorphous systems", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 134, 31 January 2019 (2019-01-31), pages 68 - 76, XP085555707, DOI: 10.1016/j.ejpb.2018.11.016
LOBMANN, KORBINIAN ET AL.: "Amino acids as co-amorphous stabilizers for poorly water soluble drugs - Part 1: Preparation, stability and dissolution enhancement", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 85, no. 3, 26 March 2013 (2013-03-26), pages 873 - 881, XP028790978, DOI: 10.1016/j.ejpb.2013.03.014
ZHU, SAIJIE ET AL.: "Co-Amorphous Formation of High-Dose Zwitterionic Compounds with Amino Acids To Improve Solubility and Enable Parenteral Delivery", MOLECULAR PHARMACEUTICS, vol. 15, no. 1, 22 November 2017 (2017-11-22), pages 97 - 107, XP055781262
WU, WENQI ET AL.: "On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 535, no. 1-2, 2 November 2017 (2017-11-02), pages 86 - 94, XP085328533
See also references of EP 3991791A4
Attorney, Agent or Firm:
TANAKA Masahiro (JP)
Download PDF: